COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Carmustine Implants in Treating Patients With Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003878
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 21, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of implanted carmustine wafers in treating patients who have brain metastases and who are undergoing surgery to remove the tumor.

Condition or disease Intervention/treatment Phase
Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: polifeprosan 20 with carmustine implant Procedure: conventional surgery Phase 2

Detailed Description:


  • Determine the local recurrence rate in patients with supratentorial metastatic brain tumors undergoing surgical resection treated with polifeprosan 20 with carmustine implant (Gliadel wafers).
  • Determine the incidence and time to recurrence at distant sites within the CNS in these patients after this treatment.
  • Determine the median, 6-month, 1-year, and 2-year survival of these patients on this regimen.
  • Determine the incidence and severity of cognitive function loss of these patients on this regimen.
  • Determine the incidence and severity of CNS and systemic toxic effects of these patients on this regimen.

OUTLINE: Patients receive up to 8 polifeprosan 20 with carmustine implants (Gliadel wafers) implanted in the resected tumor cavity.

Patients are followed on day 7 or day of discharge, at 1 month, 3 months, every 3 months for 21 months, and then for survival.

PROJECTED ACCRUAL: A total of 90 patients will be accrued for this study within 30 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: The Treatment of One or Two Supratentorial Brain Metastases With Surgical Resection and BCNU-Polymer Wafers
Study Start Date : April 2002
Actual Study Completion Date : April 2003

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Supratentorial brain metastases for which surgery is recommended

    • Solitary, unilateral, intracranial mass consistent with metastasis on MRI scan OR
    • Two brain lesions consistent with metastases on MRI scan
    • Lesions must be accessible through a single craniotomy
    • Metastatic lesions clearly distinct from tumor bed of any benign lesions
    • Intraoperative frozen section diagnosis of metastatic tumor from CNS lesion
  • No prior malignant intracranial neoplasm
  • No lesion(s) in the brainstem
  • No open communication of the resection cavity with the ventricle following resection



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • At least 3 months


  • No concurrent hematologic disorders


  • No concurrent hepatic disease


  • No concurrent renal disease


  • No concurrent cardiac disease


  • No concurrent pulmonary disorders


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Mini mental score at least 15
  • No known hypersensitivity to carmustine or Gliadel wafers
  • No other serious concurrent medical illness or infection


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • No prior cranial irradiation


  • See Disease Characteristics
  • No prior surgery involving brain metastases or primary brain tumor(s) (except for benign intracranial lesions such as pituitary adenoma, meningioma, or schwannoma)


  • Concurrent systemic therapy allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00003878

Layout table for location information
United States, Alabama
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294-3295
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612-9497
United States, Georgia
Emory University Hospital - Atlanta
Atlanta, Georgia, United States, 30322
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
United States, Massachusetts
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114-2617
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, North Carolina
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, United States, 27599-7295
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States, 27157-1030
United States, Ohio
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, United States, 19104-4283
United States, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78284-7811
Sponsors and Collaborators
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Alessandro Olivi, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Layout table for additonal information Identifier: NCT00003878    
Other Study ID Numbers: CDR0000067044
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: June 21, 2013
Last Verified: July 2003
Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific
tumors metastatic to brain
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents